Literature DB >> 17512489

Metabolic alterations in cultured mouse fibroblasts induced by an inhibitor of the tyrosine kinase receptor Fibroblast Growth Factor Receptor 1.

Fabiana Piccioni1, Anna Borioni, Maurizio Delfini, Maria Rosaria Del Giudice, Carlo Mustazza, Andrea Rodomonte, Gianfranco Risuleo.   

Abstract

Proton nuclear magnetic resonance (NMR) spectroscopy was used to identify and quantify the metabolites present in cultured mouse fibroblast cells 3T6 in their native state and after treatment with PD166866, an inhibitor of the fibroblast growth factor receptor. Cell extracts were prepared according to the Bligh-Dyer protocol which prevents artifacts deriving from the chemical demolition of macromolecules. Also the growth medium was subjected to the same extraction procedure. The NMR approach made possible the identification and quantification of about 40 different metabolites at nanomoles/mg of protein level: the biological relevance of the variation of some metabolite levels is discussed. Our experimental procedure offers a prospective method for the evaluation of variations of the metabolic profile deriving from different biochemical treatments of these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512489     DOI: 10.1016/j.ab.2007.04.013

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

Review 1.  Quantitative 1H NMR. Development and potential of an analytical method: an update.

Authors:  Guido F Pauli; Tanja Gödecke; Birgit U Jaki; David C Lankin
Journal:  J Nat Prod       Date:  2012-04-06       Impact factor: 4.050

2.  The synthetic inhibitor of fibroblast growth factor receptor PD166866 controls negatively the growth of tumor cells in culture.

Authors:  Gianfranco Risuleo; Marina Ciacciarelli; Mauro Castelli; Gaspare Galati
Journal:  J Exp Clin Cancer Res       Date:  2009-12-11

3.  Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: potential clinical use.

Authors:  Valerio Berardi; Francesca Ricci; Mauro Castelli; Gaspare Galati; Gianfranco Risuleo
Journal:  J Exp Clin Cancer Res       Date:  2009-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.